RZLT - Why Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday? | Benzinga
Tuesday, Rezolute Inc (NASDAQ:RZLT) released topline results from the Phase 2 study of RZ402 in diabetic macular edema patients who are naïve to or have received limited anti-vascular growth factor (anti-VEGF) injections.
94 participants were enrolled to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week (three-month) treatment period.
RZ402 met both primary endpoints of change in macular edema (central subfield thickness or CST) and a good safety profile.
- CST improved significantly at all RZ402 dose levels compared to ...